ALX Oncology Holdings Inc. (ALXO) vs Jyong Biotech Ltd. (MENS)

ALX Oncology Holdings Inc. and Jyong Biotech Ltd. are both Biotechnology companies. ALX Oncology Holdings Inc. and Jyong Biotech Ltd. are of similar size ($147.0M and $138.3M). Across the 5 metrics below, Jyong Biotech Ltd. leads on 3 and ALX Oncology Holdings Inc. on 2.

Valuation

Metric ALXO MENS Biotechnology median
P/E n/m — 8.50
P/S 58.97 — 9.71
P/B 1.06 n/m 2.13
Price to free cash flow n/m — 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales 8.40 n/m 9.21
Earnings yield (106.60%) — (33.15%)
Free cash flow yield (49.32%) — (25.50%)

Profitability

Metric ALXO MENS Biotechnology median
Gross margin 0.00% — 65.16%
Operating margin 0.00% — 0.00%
Net margin 0.00% — 0.00%
Free cash flow margin 0.00% — 0.00%
Return on equity (80.65%) — (56.36%)
Return on assets (63.16%) — (48.04%)
Return on invested capital (673.30%) 0.00% 0.00%

Growth

Metric ALXO MENS Biotechnology median
Revenue growth (TTM) — — 6.02%
EPS growth (last fiscal year) 26.36% (42.18%) 30.26%
Revenue growth, 5-year CAGR — — 9.41%
Net income growth, 5-year CAGR 0.00% — 0.00%

Health

Metric ALXO MENS Biotechnology median
Debt to equity 0.07 (0.74) 0.00
Current ratio 9.71 0.45 4.72
Net debt to EBITDA 0.34 (6.89) 0.96

Dividend

Metric ALXO MENS Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric ALXO MENS Biotechnology median
Market cap 138.28m 146.98m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack